NKX2-1 and cancer: Recently, it has been demonstrated that neutrophil plasticity and heterogeneity underlie adverse events that may result in the discontinuation of immunotherapy.[9] Previous reports have shown that SOX2 is a critical TF that recruits neutrophils into the TME by regulating CXCL3 and CXCL5 expression, thus facilitating cancer progression.[17] However, the implication of NKX2‐1 in attracting immune cells to the TME and mediating the progression of LUAD remains unclear.